LAUSANNE-UNIVERSITY-HOSP
A study, published yesterday in Nature Medicine , has shown that T follicular helper (Tfh) cells serve as the dominant cell reservoir for HIV infection. The study was led by Professors Matthieu Perreau and Giuseppe Pantaleo from the Service of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.
The researchers have investigated the HIV reservoir in aviremic individuals treated for several years (up to 14 years) with antiretroviral (ART) therapy. The study demonstrates that a population of CD4 T cells residing within the germinal centers of lymph nodes, known as Tfh cells, serves as the dominant cell reservoir for HIV infection. The Tfh cells which represent less than 1% of total CD4 T cells in long-term ART treated individuals, contained replication competent and infectious virus. Germinal centers are difficult to access to cytotoxic CD8 T cells and thus represent a privileged anatomic site, e.g. a sanctuary, for the persistence of HIV in Tfh cells in long-term ART treated individuals.
Despite the major advances in ART therapy and the effective suppression of HIV replication, ART is not capable of eliminating HIV. HIV invariably rebounds after ART interruption and therefore life-time ART therapy is currently required for controlling virus replication. The present study appeared in Nature Medicine shed light on a fundamental issue, i.e. the identification of the cells that may be responsible for the rapid rebound of virus replication following ART interruption.
“The identification of Tfh cells as the major cell compartment containing replication competent and infectious HIV represents a major advance in our understanding of the mechanisms of HIV persistence following many years of ART-mediated virus suppression”, says Prof. Matthieu Perreau.
“We are very excited of the identification of Tfh cells as the major cell reservoir for HIV in long-term treated individuals. These observations will promote the development of therapeutic immune-based interventions that can directly target the HIV cell reservoir and have substantial impact in accelerating research in the fields of HIV functional cure and eradication”, says Prof. Pantaleo.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005501/en/
Contact:
Lausanne University Hospital
Prof. Giuseppe Pantaleo
Giuseppe.Pantaleo@chuv.ch
or
Matthieu
Perreau
Matthieu.Perreau@chuv.ch
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom